HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

FDA approval expands range of Metadate (methylphenidate) dosages

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Medadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Metadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).

The capsules are already available in 10 mg, 20 mg, and 30 mg strengths, with a recommended starting dose of 20 mg once daily.

"The new strengths will allow for the full range of immediate-release doses (30% of the total) from a single capsule," said James M. Swanson, MD, PhD, professor of pediatrics at the University of California, Irvine. "The addition of these doses will allow physicians greater flexibility in tailoring a treatment regimen to the individual needs and responses of each patient."